Phase 2 Study in Patients With MiT Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00557609
Recruitment Status : Completed
First Posted : November 14, 2007
Last Update Posted : February 8, 2013
Information provided by (Responsible Party):

November 12, 2007
November 14, 2007
February 8, 2013
October 2007
December 2010   (Final data collection date for primary outcome measure)
Determine the overall response rate (ORR) in patients treated with ARQ 197
Same as current
Complete list of historical versions of study NCT00557609 on Archive Site
  • Evaluate progression-free survival (PFS) time in patients treated with ARQ 197
  • Evaluate 6-month and 1-year overall survival (OS) rates in patients treated with ARQ 197
  • Further characterize the safety of ARQ 197 in adolescent and young adult patients with MiT tumors
Same as current
Not Provided
Not Provided
Phase 2 Study in Patients With MiT Tumors
A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors
This is a multi-center, single arm intended to evaluate the anti-tumor effect of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. MiT tumors include clear cell sarcoma, alveolar soft parts sarcoma, and translocation associated renal cell carcinoma.

This is a multi-center, single arm, two-stage phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. ARQ 197 is a novel small molecule drug designed to block the activity of c-Met, which is thought to play multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis.

The microphthalmia transcription factor tumors (MiT tumors) are clear cell sarcoma (CCS), alveolar soft part sarcoma (ASPS), and translocation associated renal cell carcinoma (RCC). These soft tissue cancers are characterized by a common transcriptional mechanism that leads to inexorable spread and resistance to all known therapies. They tend to strike adolescents and young adults, and are invariably fatal if not resectable at diagnosis. Several academic laboratories have shown that genetic translocations in these tumors upregulate c-Met, and that such tumors are dependent upon this activity.

The study will enroll adolescent (age 13 or older) and adult patients with a histologically or cytologically confirmed MiT malignant disease. Eligible patients will receive ARQ 197 twice daily. Treatment will be continued until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.

During the study, tumor evaluations will be performed at baseline, then in 8-week intervals.

To evaluate each patient's safety and the drug's toxicity, physical examinations, laboratory evaluations, vitals signs, and adverse event assessments will be performed throughout the study. Blood samples for PK analysis will be collected during first cycle of treatment from up to 10 patients aged 20 or younger. Archival tissue specimens and relevant laboratory results on patients' gene translocation/fusion status will be collected.

Tumor biopsies may also be collected (optional) with patient's consent. If patients agree tumor samples may be collected using core needle biopsy.

In addition, to explore biological responses of tumors to ARQ 197 treatment, FDG-PET scanning will be performed at three time points: within 14 days prior to the treatment, on Day 8 (± 2 days) of Cycle 1 and after two cycles of treatment coinciding with tumor measurement.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Renal Cell Carcinoma (RCC)
  • Alveolar Soft Part Sarcoma (ASPS)
  • Clear Cell Sarcoma (CCS)
Drug: ARQ 197
360 mg administered twice daily until disease progression or other discontinuation criterion is met
Not Provided
Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 1;118(23):5894-902. doi: 10.1002/cncr.27582. Epub 2012 May 17.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2011
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically or cytologically confirmed unresectable locally advanced or metastatic alveolar soft part sarcoma, clear cell sarcoma, or translocation associated renal cell carcinoma
  2. ≥13 years old
  3. Male or female patients of child-producing potential must agree to use double barrier contraception, oral contraceptives or avoidance of pregnancy measures during the study and for 30 days after the last ARQ 197 dose
  4. Females of childbearing potential must have a negative serum pregnancy test

Exclusion Criteria:

  1. Central nervous system metastasis unless it has been stable for ≥ 3 months after treatment and patient has no neural symptoms
  2. Pregnant or lactating
  3. Significant gastrointestinal disorder(s), in the opinion of a Investigator, could interfere with the absorption of ARQ 197 (e.g., Crohn's disease, ulcerative colitis, extensive gastric or small bowel resection)
  4. Unable or unwilling to swallow ARQ 197 capsules twice daily
  5. Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  6. Bradycardia at baseline or known history of arrhythmia
  7. Received ARQ 197 previously
Sexes Eligible for Study: All
13 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Canada,   United Kingdom,   United States
ARQ 197-204
Not Provided
Not Provided
Not Provided
Not Provided
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP